Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of immunoglobulin and cell growth factor in preparing medicine for asthma

A technology of immunoglobulin and growth factor, applied in the field of active drugs composed of secretory immunoglobulin A and epithelial cell growth factor EGF, can solve the problems of uncertain curative effect, difficult cure, and inability to desensitize, and achieve the elimination of important induced Factors, Significant Curative Effects

Active Publication Date: 2007-05-02
翁维楷 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current treatment methods include: (1) β-receptor stimulants relax bronchial smooth muscle to achieve seizure relief, but relapse after drug withdrawal; (2) corticosteroids: play non-specific anti-inflammatory effects, and in recent years, aerosol small-dose inhalation therapy has been used. (3) desensitization therapy: regular injection of allergens for desensitization, and repeated injections for many years are difficult to persist; and more than 100 kinds of allergens have been found, some of which have uncertain curative effects, and some unable to desensitize

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation of active drug consisting of secretory immunoglobulin A (sIgA) and epithelial growth factor EGF:

[0047] (1) Place 1,000 grams of human colostrum at a temperature of 0° C., centrifuge in a centrifuge at 10,000 rpm, and collect the separation liquid containing sIgA;

[0048] (2) Separation by an ultrafiltration membrane with a pore size of 0.01 μm to further remove impurities, and then adopt conventional methods and sterilize to obtain 100 grams of separation liquid, which is tested by agar diffusion, wherein: contains 5 mg / g of sIgA;

[0049] (3) Freeze-dry the above 100 grams of ultrafiltration membrane separation liquid at a temperature of -10° C. to obtain 10 grams of powder containing secretory immunoglobulin A (sIgA), wherein: 5 grams of sIgA are contained;

[0050] (4) Add 0.005 g of epithelial cell growth factor EGF prepared by the genetic engineering method produced by Dajiang Company, stir evenly, and obtain the active drug.

[0051] Preparation o...

Embodiment 2

[0054] (1) Place 1,000 grams of human colostrum at a temperature of 4° C., centrifuge in a centrifuge at 15,000 rpm, and collect the separated liquid containing sIgA;

[0055] (2) Separation by an ultrafiltration membrane with a pore size of 0.02 μm to further remove impurities, and then adopt conventional methods and sterilize to obtain 100 grams of separation liquid, which is tested by agar diffusion method, wherein: 4 mg / g of sIgA is contained;

[0056] (3) Freeze-dry the above 100 grams of ultrafiltration membrane separation liquid at a temperature of -30° C. to obtain 10 grams of powder containing secretory immunoglobulin A (sIgA), wherein: 4 grams of sIgA are contained;

[0057] (4) Add 0.08 g of epithelial cell growth factor EGF prepared by the genetic engineering method produced by Dajiang Company, and stir evenly to obtain the active drug.

[0058] Preparation of tablets:

[0059] Using a method known in the field of preparations, the above-mentioned active drug, an ...

Embodiment 3

[0061] Specific cases:

[0062] 1. Yu, male, 3 years old, had a childhood asthma attack, which was ineffective after being treated with various drugs, and the asthma was attacking when he came. The spray of Example 1 was used several times a day for one week of treatment, and the symptoms and signs disappeared and relieved. , A total of 1 month of treatment was discontinued, and no recurrence was found in more than 10 years of follow-up.

[0063] 2. Zhang Moumou, male, 9 years old. The patient had asthma for 7 years, and it was ineffective through routine treatment with asthma medicines. When the patient came, the asthma was just breaking out. The tablet treatment of Example 2 was used, 3 times a day, each 6 tablets, totally 7 days, and the symptoms and signs disappeared and relieved. A total of 1 month of treatment was stopped, and no recurrence was found in the 10-year follow-up. He is studying in university.

[0064] 3. Wu Moumou, male, 34 years old, driver, has suffered ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses the use of immunoglobulin and cell growth factor in the preparation of medicaments for treating asthma, wherein the mechanism of action for the treatment includes, (1) the sIgA covering the top layer of the bronchus mucosa, thus blocing the antigens entering human body through the mucosa, (2) eradicating the bacteria and virus intruded into human body, (3) the growth factor EGF restoring the respiratory tract and branch trachea damaged mucosa and tissue, thus the tracing allergic reaction would not occur after antigens intrusion after stopping the drugs.

Description

technical field [0001] The invention relates to a medicine for treating bronchial asthma, in particular to an active medicine composed of secretory immunoglobulin A (sIgA) isolated from human colostrum and epithelial cell growth factor EGF. Background technique [0002] There are more than 100 million people with bronchial asthma in the world, and the prevalence rate is still rising. Current treatment methods include: (1) β-receptor stimulants relax bronchial smooth muscle to achieve seizure relief, but relapse after drug withdrawal; (2) corticosteroids: play non-specific anti-inflammatory effects, and in recent years, aerosol small-dose inhalation therapy has been used. (3) desensitization therapy: regular injection of allergens for desensitization, and repeated injections for many years are difficult to persist; and more than 100 kinds of allergens have been found, some of which have uncertain curative effects, and some Unable to detoxify. Contents of the invention [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K38/18A61P11/06
Inventor 翁维楷朱湘雯
Owner 翁维楷